Skip to content

Amneal Pharmaceuticals, Inc.

AMRX· NasdaqCore metricsCIK 1723128

Pharmaceutical preparations551 peers

Last sale
Oct 30, 2026 · +0.82%
Market cap
$7.49B
348.41M shares
Filings
695
$862.68M
Q3 2026+8.0% FY25 yoy
-$21.70M
Q3 2026N/M FY25 yoy
$95.42M
Q3 2026+58.1% FY25 yoy
-$20.35M
Q3 2026derived+11.0% FY25 yoy
-$0.06
Q3 2026N/M FY25 yoy
$157.40M
Q3 2026+155.1% FY25 yoy
$7.49B
56.2×
2.3×
14.1×
1.18%
—

Twelve months to Sep 30, 2026 · derived

Price

$21.51+106.63%+$11.10past year
Oct 30, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$3.02BFY 2025
$3.02B0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$3,018,760,000reported
FY 20242024-12-31$2,793,957,000reported
FY 20232023-12-31$2,393,607,000reported
FY 20222022-12-31$2,212,304,000reported
FY 20212021-12-31$2,093,669,000reported
FY 20202020-12-31$1,992,523,000reported
FY 20192019-12-31$1,626,373,000reported
FY 20182018-12-31$1,662,991,000reported
FY 20172017-12-31$1,033,654,000reported
FY 20162016-12-31$1,018,225,000reported

Capital returns

Dividends and buybacks · FY2016 to FY2020
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2020$0.00—$0.00———0.0%
FY2019$0.00—$0.00————
FY2018$183.00M—$183.00M———109.5%
FY2017$375.27M—$375.27M—1.00K sh—269.2%
FY2016$200.62M$5.00K$200.62M————

Segments

Revenue by Segments, FY2018 to FY2025FY2018Specialty · FY2018 · $223.96MGenerics · FY2018 · $1.44BSpecialty · FY2018 · $223.96MFY2019Specialty · FY2019 · $317.53MGenerics · FY2019 · $1.31BSpecialty · FY2019 · $317.53MFY2020AvKARE · FY2020 · $293.75MSpecialty · FY2020 · $355.57MAv Kare · FY2020 · $293.75MGenerics · FY2020 · $1.34BSpecialty · FY2020 · $355.57MFY2021AvKARE · FY2021 · $349.01MSpecialty · FY2021 · $378.32MAv Kare · FY2021 · $349.01MGenerics · FY2021 · $1.37BSpecialty · FY2021 · $378.32MFY2022Affordable Medicines · FY2022 · $1.43BAvKARE · FY2022 · $406.11MSpecialty · FY2022 · $374.12MGenerics · FY2022 · $1.43BSpecialty · FY2022 · $374.12MFY2023Affordable Medicines · FY2023 · $1.47BAvKARE · FY2023 · $531.75MSpecialty · FY2023 · $390.46MGenerics · FY2023 · $1.47BFY2024Affordable Medicines · FY2024 · $1.69BAvKARE · FY2024 · $662.95MSpecialty · FY2024 · $445.75MFY2025Affordable Medicines · FY2025 · $1.75BAvKARE · FY2025 · $744.73MSpecialty · FY2025 · $528.51M
LineFY2025ShareChange
Affordable Medicines$1.75B58%+3.6%
AvKARE$744.73M25%+12.3%
Specialty$528.51M18%+18.6%
Av Kare———
Generics———
Specialty———
Total$3.02B

From the 10-K filed Feb 27, 2026AMRX

Pharmaceutical preparations

Amneal Pharmaceuticals, Inc. is the 25th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR